Employees Retirement System of Texas Purchases 8,823 Shares of Icon Plc $ICLR

Employees Retirement System of Texas boosted its position in Icon Plc (NASDAQ:ICLR) by 4.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 228,523 shares of the medical research company’s stock after buying an additional 8,823 shares during the period. Employees Retirement System of Texas owned approximately 0.28% of Icon worth $39,992,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Geneos Wealth Management Inc. raised its position in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. Spire Wealth Management boosted its position in shares of Icon by 10.1% during the 3rd quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 62 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares in the last quarter. Sierra Legacy Group grew its stake in Icon by 2.5% during the third quarter. Sierra Legacy Group now owns 4,540 shares of the medical research company’s stock worth $794,000 after purchasing an additional 110 shares during the period. Finally, SkyView Investment Advisors LLC increased its holdings in Icon by 1.8% in the second quarter. SkyView Investment Advisors LLC now owns 6,321 shares of the medical research company’s stock worth $914,000 after purchasing an additional 113 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Price Performance

Shares of ICLR opened at $97.45 on Friday. The business’s fifty day moving average is $145.89 and its 200 day moving average is $166.01. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a market cap of $7.87 billion, a P/E ratio of 13.19, a P/E/G ratio of 2.70 and a beta of 1.35.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ICLR. BMO Capital Markets restated a “market perform” rating and set a $100.00 price target on shares of Icon in a report on Thursday, February 12th. Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 25th. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the stock a “neutral” rating in a report on Tuesday, February 17th. Barclays decreased their price target on shares of Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday. Finally, Mizuho set a $216.00 price objective on shares of Icon in a research report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $146.80.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.